CoChat
Sign Up
Cited by 64Neurological Disorders and TreatmentsNeurological Disease Mechanisms and TreatmentsNeuroscience and Neuropharmacology Research

A unique array of neuroprotective effects of pyruvate in neuropathology

Open access
Zilberter, Yuri, Gubkina, Olena, Ivanov, Anton I.·2015·Frontiers in Neuroscience
DOI 10.3389/fnins.2015.00017PMC PMC4330789
Open this paper in CoChat — free accountOpen PDF

Abstract

The three common signature characteristics of many neurological diseases are brain hypometabolism, oxidative stress, and neuroinflammation (Melo et al., 2011; Cai et al., 2012; Heneka et al., 2014). In order to be efficient, successful treatment should targetall three pathologies simultaneously. Pyruvate seems to be an ideal candidate for such a treatment because of its unique combination of neuroprotective effects (Figure 1). In this opinion paper, we attempt to review and summarize recent information concerningthese effects and their significance for neuroprotection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2015.00017

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. Abeti R. Abramov A. Y. Duchen M. R. (2011). Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 134, 1658– 1672. 10.1093/brain/awr104 21616968 · DOI
  2. Abeti R. Duchen M. R. (2012). Activation of PARP by oxidative stress induced by beta-amyloid: implications for Alzheimer's disease. Neurochem. Res. 37, 2589– 2596. 10.1007/s11064-012-0895-x 23076628 · DOI
  3. Abramov A. Y. Duchen M. R. (2005). The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360, 2309– 2314. 10.1098/rstb.2005.1766 16321801 PMC1569597 · DOI
  4. Alvarez G. Ramos M. Ruiz F. Satrustegui J. Bogonez E. (2003). Pyruvate protection against beta-amyloid-induced neuronal death: role of mitochondrial redox state. J. Neurosci. Res. 73, 260– 269. 10.1002/jnr.10648 12836169 · DOI
  5. Amatniek J. C. Hauser W. A. Delcastillo-Castaneda C. Jacobs D. M. Marder K. Bell K.. (2006). Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47, 867– 872. 10.1111/j.1528-1167.2006.00554.x 16686651 · DOI
  6. Andrabi S. A. Umanah G. K. Chang C. Stevens D. A. Karuppagounder S. S. Gagne J. P.. (2014). Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc. Natl. Acad. Sci. U.S.A. 111, 10209– 10214. 10.1073/pnas.1405158111 24987120 PMC4104885 · DOI · Paper page
  7. Cai H. Cong W. N. Ji S. Rothman S. Maudsley S. Martin B. (2012). Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr. Alzheimer Res. 9, 5– 17. 10.2174/156720512799015064 22329649 PMC4097094 · DOI
  8. Carvalho A. S. Torres L. B. Persike D. S. Fernandes M. J. Amado D. Naffah-Mazzacoratti Mda G.. (2011). Neuroprotective effect of pyruvate and oxaloacetate during pilocarpine induced status epilepticus in rats. Neurochem. Int. 58, 385– 390. 10.1016/j.neuint.2010.12.014 21185899 · DOI
  9. Clark R. S. Vagni V. A. Nathaniel P. D. Jenkins L. W. Dixon C. E. Szabo C. (2007). Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. J. Neurotrauma 24, 1399– 1405. 10.1089/neu.2007.0305 17711401 · DOI
  10. Das U. N. (2006). Is pyruvate an endogenous anti-inflammatory molecule? Nutrition 22, 965– 972. 10.1016/j.nut.2006.05.009 16814517 · DOI
  11. Desagher S. Glowinski J. Premont J. (1997). Pyruvate protects neurons against hydrogen peroxide-induced toxicity. J. Neurosci. 17, 9060– 9067. 9364052 PMC6573585
  12. Fukushima M. Lee S. M. Moro N. Hovda D. A. Sutton R. L. (2009). Metabolic and histologic effects of sodium pyruvate treatment in the rat after cortical contusion injury. J. Neurotrauma 26, 1095– 1110. 10.1089/neu.2008.0771 19594384 PMC2848946 · DOI
  13. Gottlieb M. Wang Y. Teichberg V. I. (2003). Blood-mediated scavenging of cerebrospinal fluid glutamate. J. Neurochem. 87, 119– 126. 10.1046/j.1471-4159.2003.01972.x 12969259 · DOI
  14. Holleman A. F. (1904). Notice sur l'action de l'eau oxygénée sur les acides α−cétoniques et sur les dicétones 1. 2. Recueil des Travaux Chimiques des Pays-Bas et de la Belgique 23, 169– 172 10.1002/recl.19040230504 · DOI
  15. Isopi E. Granzotto A. Corona C. Bomba M. Ciavardelli D. Curcio M.. (2014). Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology. Neurobiol. Dis. [Epub ahead of print]. 10.1016/j.nbd.2014.11.013 25434488 · DOI
  16. Kao K. K. Fink M. P. (2010). The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem. Pharmacol. 80, 151– 159. 10.1016/j.bcp.2010.03.007 20230800 · DOI
  17. Lee J. Y. Kim Y. H. Koh J. Y. (2001). Protection by pyruvate against transient forebrain ischemia in rats. J. Neurosci. 21: RC171. 11588201 PMC6763857
  18. Ma Y. Chen H. He X. Nie H. Hong Y. Sheng C.. (2012). NAD+ metabolism and NAD(+)-dependent enzymes: promising therapeutic targets for neurological diseases. Curr. Drug Targets 13, 222– 229. 10.2174/138945012799201711 22204321 · DOI
  19. Melo A. Monteiro L. Lima R. M. Oliveira D. M. Cerqueira M. D. El-Bacha R. S. (2011). Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxid. Med. Cell. Longev. 2011: 467180. 10.1155/2011/467180 22191013 PMC3236428 · DOI
  20. Minkeviciene R. Rheims S. Dobszay M. B. Zilberter M. Hartikainen J. Fülöp L.. (2009). Fibrillar β-amyloid-induced hyperexcitability of cortical and hippocampal neurons triggers progressive epilepsy. J. Neurosci. 29, 3453– 3462. 10.1523/JNEUROSCI.5215-08.2009 19295151 PMC6665248 · DOI
  21. Mongan P. D. Karaian J. Van Der Schuur B. M. Via D. K. Sharma P. (2003). Pyruvate prevents poly-ADP ribose polymerase (PARP) activation, oxidative damage, and pyruvate dehydrogenase deactivation during hemorrhagic shock in swine. J. Surg. Res. 112, 180– 188. 10.1016/S0022-4804(03)00148-3 12888336 · DOI
  22. Moroni F. Chiarugi A. (2009). Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J. 276, 36– 45. 10.1111/j.1742-4658.2008.06768.x 19087198 · DOI
  23. Noebels J. (2011). A perfect storm: converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia (Suppl. 1), 39– 46. 10.1111/j.1528-1167.2010.02909.x 21214538 PMC3058398 · DOI
  24. Satchell M. A. Zhang X. Kochanek P. M. Dixon C. E. Jenkins L. W. Melick J.. (2003). A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma. J. Neurochem. 85, 697– 708. 10.1046/j.1471-4159.2003.01707.x 12694396 · DOI
  25. Sharma P. Benford B. Li Z. Z. Ling G. S. (2009). Role of pyruvate dehydrogenase complex in traumatic brain injury and Measurement of pyruvate dehydrogenase enzyme by dipstick test. J. Emerg. Trauma Shock 2, 67– 72 10.4103/0974-2700.50739 19561963 PMC2700588 · DOI
  26. Shetty P. K. Sadgrove M. P. Galeffi F. Turner D. A. (2012). Pyruvate incubation enhances glycogen stores and sustains neuronal function during subsequent glucose deprivation. Neurobiol. Dis. 45, 177– 187 10.1016/j.nbd.2011.08.002 21854850 PMC3224180 · DOI
  27. Simeone K. A. Matthews S. A. Samson K. K. Simeone T. A. (2014). Targeting deficiencies in mitochondrial respiratory complex I and functional uncoupling exerts anti-seizure effects in a genetic model of temporal lobe epilepsy and in a model of acute temporal lobe seizures. Exp. Neurol. 251, 84– 90. 10.1016/j.expneurol.2013.11.005 24270080 PMC3990438 · DOI
  28. Smith J. A. Park S. Krause J. S. Banik N. L. (2013). Oxidative stress, DNA damage, and the telomeric complex as therapeutic targets in acute neurodegeneration. Neurochem. Int. 62, 764– 775. 10.1016/j.neuint.2013.02.013 23422879 PMC3619128 · DOI
  29. Stein L. R. Imai S. (2012). The dynamic regulation of NAD metabolism in mitochondria. Trends Endocrinol. Metab. 23, 420– 428. 10.1016/j.tem.2012.06.005 22819213 PMC3683958 · DOI
  30. Suh S. W. Aoyama K. Chen Y. Garnier P. Matsumori Y. Gum E.. (2003). Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J. Neurosci. 23, 10681– 10690. 14627653 PMC6740913
  31. Suh S. W. Aoyama K. Matsumori Y. Liu J. Swanson R. A. (2005). Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment. Diabetes 54, 1452– 1458. 10.2337/diabetes.54.5.1452 15855333 · DOI · Paper page
  32. Teichberg V. I. Cohen-Kashi-Malina K. Cooper I. Zlotnik A. (2009). Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 158, 301– 308. 10.1016/j.neuroscience.2008.02.075 18423998 · DOI
  33. Waldbaum S. Patel M. (2010). Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res. 88, 23– 45. 10.1016/j.eplepsyres.2009.09.020 19850449 PMC3236664 · DOI
  34. Wang Y. Qin Z. H. (2010). Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis 15, 1382– 1402. 10.1007/s10495-010-0481-0 20213199 · DOI
  35. Ying W. Chen Y. Alano C. C. Swanson R. A. (2002). Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. J. Cereb. Blood Flow Metab. 22, 774– 779. 10.1097/00004647-200207000-00002 12142562 · DOI
  36. Zilberter M. Ivanov A. Ziyatdinova S. Mukhtarov M. Malkov A. Alpar A.. (2013). Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease. J. Neurochem. 125, 157– 171. 10.1111/jnc.12127 23241062 · DOI
  37. Zlotnik A. Gurevich B. Cherniavsky E. Tkachov S. Matuzani-Ruban A. Leon A.. (2008). The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem. Res. 33, 1044– 1050. 10.1007/s11064-007-9548-x 18080187 · DOI
  38. Zlotnik A. Sinelnikov I. Gruenbaum B. F. Gruenbaum S. E. Dubilet M. Dubilet E.. (2012). Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats. Anesthesiology 116, 73– 83. 10.1097/ALN.0b013e31823d7731 22129535 · DOI

Cited by

Sorted by citations

Authors
Zilberter, Y., Gubkina, O., & Ivanov, A. I.
Affiliations
Inserm (FR)
Corresponding author
Zilberter, Yuri
ORCID
Venue
Frontiers in Neuroscience
Publisher
Frontiers Media SA
Published
2015-02-17
Volume
9
Issue
17
Pages
17-17
ISSN
1662-453X (ISSN-L)
DOI
10.3389/fnins.2015.00017
PMC
PMC4330789
OpenAlex
W2073778161
Cited by
64
References
2
Citations by year
2026: 5 · 2025: 9 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 3 · 2020: 8 · 2019: 1 · 2018: 7 · 2017: 6 · 2016: 7 · 2015: 1
FWCI
3.44
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Alzheimer's Association (NESAD-12-242486)
Topics
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
pyruvate, neuroprotection, neuropathology, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review